Investing.com — stock surged 13.4% in premarket trading Thursday after the company announced new mechanistic data for its lead drug candidate EB-003, demonstrating the compound’s activation of dual signaling pathways linked to antidepressant and anxiolytic effects.
The Cambridge, Massachusetts-based biotechnology company revealed that proprietary assays showed EB-003 activates both Gq- and β-arrestin-mediated signaling downstream of the 5-HT₂A receptor. According to Enveric, multiple peer-reviewed studies have previously shown that activation of either pathway can independently produce antidepressant- and anxiolytic-like effects in preclinical models.
The company developed its own bioluminescence resonance energy transfer (BRET) assays to characterize EB-003’s intracellular signaling profile after finding that commercial assays capable of reliably measuring pathway-specific 5-HT₂A signaling were not available.
Enveric also highlighted a recent independent study published in Nature that provides additional mechanistic clarity regarding signaling downstream of 5-HT₂A. The study reported that Gi signaling was required for hallucinogenic effects, while Gq signaling mediated antidepressant- and anxiolytic-like benefits in preclinical systems, suggesting therapeutic benefits and hallucinations may arise from distinct intracellular pathways.
“Growing mechanistic clarity around 5-HT₂A signaling strengthens confidence in the scientific foundation of our platform,” said Joseph Tucker, Ph.D., CEO of Enveric Biosciences. “Our proprietary BRET assay data show that EB-003 engages signaling pathways that prior peer-reviewed studies have linked to antidepressant- and anxiolytic-like effects in preclinical models.”
Enveric is developing EB-003 as a non-hallucinogenic neuroplastogen intended to support streamlined treatment paradigms, including potential at-home administration. The company continues to advance the drug candidate through IND-enabling studies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.